Skip to main content
OpenTrials
Completed

NCT Number: NCT01025037

Outcomes in Rotator Cuff Repair Using Graft Reinforcement

The purpose of this study is to evaluate patient shoulder functional outcomes following rotator cuff repairs reinforced with a surgical mesh.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orthopaedic Clinical Association, Phoenix, Arizona, United States

Loading trial locations.

About this study

Conexa is a surgical mesh derived from porcine dermis and processed to produce an acellular dermal matrix. It is designed to perform as a surgical mesh for use as a soft tissue patch to reinforce soft tissue where weaknesses exist and for the surgical repair of damaged or ruptured soft tissue membranes. The purpose of this post-market clinical study is to collect safety and efficacy data when Conexa is used to repair torn tendons of the rotator cuff. Conexa will be used in accordance with its labeling for this clinical study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The patient:

  • is an adult male or female between the ages of 40-70 years old;
  • has repairable primary large retracted two-tendon rotator cuff tears measuring from 3 cm to 5 cm;
  • requires surgical repair of single rotator cuff (i.e. one limb);
  • has movement of the non-operative arm defined as shoulder elevation of equal to or greater than 90 degrees and is able to perform postoperative exercises;
  • is able to return for all scheduled and required study visits;
  • is able to provide written informed consent for study participation.

Exclusion criteria

The patient:

  • has irreparable large rotator cuff tears that are found intra-operatively. Note: irreparable is defined by the inability to approximate the tendon to the tuberosity without tension;
  • has a rotator cuff tear < 3cm (measured intra-operatively);
  • has a rotator cuff tear > 5cm (measured intra-operatively);
  • has a rotator cuff tear where the subscapularis tendon is disrupted/requires repair;
  • has grade 3 or 4 fatty infiltration of the rotator cuff;
  • has had prior surgical repair to the affected shoulder;
  • is American Society of Anesthesiologists (ASA) Class 4 or 5 (See Appendix I);
  • is a tobacco user; unless tobacco free 6 months prior to surgery and willing to remain tobacco free for the duration of the study.
  • has lower limb injuries requiring walking assist devices such as crutches and walkers;
  • has a known collagen disorder, including systemic lupus erythematous (SLE), rheumatoid arthritis (RA), polymyositis, scleroderma, ankylosing spondylitis, dermatomyositis, osteogenesis imperfecta or the inherited disorders of Sjogren, Larsen, Raynaud, Ehlers-Danlos or Marfan syndrome.
  • has obstacles that pose an inordinately high surgical risk, in the judgment of the certified surgeon;
  • has co-morbid factors which predispose to postoperative infection, such as insulin dependent diabetes, chronic steroid use, malnourishment, cancer, or co-existent infection;
  • has a history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction;
  • is enrolled or plans to enroll in another clinical trial during this study that would affect the patient's safety or results of this trial;
  • has any of the conditions identified within the labeled contraindications, i.e. sensitivity to porcine derived products or polysorbate.
  • has an inability to have a closed MRI conducted.
  • needs a re-operation for a re-tear of the rotator cuff.

Treatment and study plan

Conexa Reconstructive Tissue Matrix

Device

Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures

Other names: Conexa, Conexa TM

Primary outcomes

  1. American Shoulder and Elbow Score (ASES)

    Time frame: baseline, post-op months 3, 6, 12, and 24

    The ASES evaluation generally has a patient self-evaluation section and a physician assessment section. The patient self-evaluation section of the form contains visual analog scales for pain, instability, an activities of daily living (ADL) questionnaire. The physician assessment section includes an area to collect demographic information and assesses range of motion, specific physical signs, strength, and stability. A shoulder score can be derived from the visual analogue scale score for pain (50%) and the cumulative activities of daily living score (50%) (Richards, Bigliani, Gartsman, Iannotti, & Zuckerman, 1994). The ASES evaluation has a total of 100 points possible; with 100 being the best possible outcome, and 0 being the worst.

  2. Adjusted Constant-Murley Score

    Time frame: baseline, post-op months 6, 12, and 24

    The Constant-Murley Shoulder Score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (Activities of Daily Living - sleep, work, recreation/sport) (20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment) (40 points) and strength (25 points), for a total of 65 points (Stiller & Uhl, 2005).

  3. Simple Shoulder Test (SST)

    Time frame: baseline, post-op months 3, 6, 12, and 24

    The Simple Shoulder Test (SST): a series of 12 "yes" or "no" questions the patient answers about the function of the involved shoulder; 2 questions relate to pain, 7 questions relate to function and 3 questions relate to range of motion. The answers to these questions (yes = 1, no = 0) provides a standardized way of recording the function of a shoulder before and after treatment (McClure & Michener, 2003). A score of 12 on the Simple Shoulder test represents the best possible outcome, while a score of 0 represents the worst possible outcome.

Secondary outcomes

  1. Rotator Cuff Re-tear Evaluation

    Time frame: Post-op months 6 and 12

    Subjects will have MRI to assess healing of the repaired tendon at 6 and 12 months post-op. The rate of re-tear will be reported.

    Two different definitions of a re-tear were used for the analysis.

    • Primary definition (used for analysis of the secondary objective): Full thickness tear that is 80% or greater in length of the original tear size.
    • Sub-analysis: Full thickness tear one centimeter or greater in length.
  2. Isometric Strength

    Time frame: baseline, post-op months 6, 12, and 24

Other outcomes

  1. Incidence of Complications, Including Infection

    Time frame: All time points

    Complications were summarized by reporting adverse events of special interest. AEs of special interest were defined as any reported infection (incision, wound, surgical site), seroma, hematoma, inflammation (surgical site, wound), and re-tear. The re-tear rate reported in this section is the number reported via AE or surgical intervention (not the MRI results). The AEs of special interest were chosen because they are in alignment with the potential complications listed on the product insert.

Sponsors and collaborators

Lead sponsor

Stryker Trauma and Extremities

Industry

Collaborators

  • LifeCell

Registry information

Official study title

A Prospective, Multi-Center, Single-Arm Study to Assess Clinical Outcomes In Primary Open or Mini-Open Rotator Cuff Repair Using Conexa Graft Reinforcement

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
Dec 3, 2009
Registry last updated
Jan 26, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.